Article PDF first page preview

First page of Downregulation of Signal Transducer and Activator of Transcription 4 (STAT4) contributes to impaired osteogenic differentiation of human bone marrow stem cells (hBMSCs) during in vitro expansion

Introduction: In vitro expansion of primary human bone marrow stem cells (hBMSCs) is necessary to obtain sufficient cells for therapeutic uses. Unfortunately, hBMSCs rapidly lose their osteogenic differentiation potential during expansion, significantly limiting their applications. Signal transducer and activator of transcription 4 (STAT4) is known to play roles in cell migration, proliferation, and differentiation. This study aims to determine the expression and the role of STAT4 during the expansion of hBMSCs. Methods: STAT4 expression in different passages of hBMSCs was evaluated using qRT-PCR and Western blotting. RNA interference and adeno-associated virus serotype 2 (AAV2)-mediated gene overexpression were employed to assess the function of STAT4. RNA samples from STAT4-overexpressing hBMSCs were analyzed by RNA-seq to identify differentially expressed genes (DEGs), followed by bioinformatics analyses to determine the pathways affected by STAT4. Results: STAT4 expression progressively decreases during the in vitro expansion of hBMSCs, concomitant with the loss of osteogenic differentiation potential. STAT4 knockdown in early passage hBMSCs significantly inhibits their osteogenic differentiation, evidenced by markedly reduced calcium deposition and downregulation of osteogenic markers. STAT4 knockdown also reduces hBMSCs’ proliferation ability. Conversely, STAT4 overexpression notably increases calcium deposition in passage 3 to passage 7 cells, suggesting that enhanced STAT4 expression can mitigate the loss of osteogenic potential during hBMSC expansion. Transcriptomic analysis revealed DEGs in STAT4-overexpressing hBMSCs. Subsequent bioinformatics analyses indicated that some of these DEGs are involved in pathways regulating cell differentiation and senescence. Conclusion: The in vitro expansion of hBMSCs leads to the downregulation of STAT4, which contributes to the impairment of their osteogenic potential and may affect cell self-renewability. This study provides insight into the molecular mechanisms underlying the loss of osteogenic differentiation during hBMSC expansion and identifies STAT4 as a potential target for hBMSC-based bone regeneration therapies.

Journal Section:
Stem Cells
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.